CVS Health’s (CVS) “Buy” Rating Reaffirmed at UBS Group

UBS Group reaffirmed their buy rating on shares of CVS Health (NYSE:CVS) in a research note released on Thursday. UBS Group currently has a $78.00 price objective on the pharmacy operator’s stock.

A number of other brokerages have also commented on CVS. Cowen set a $76.00 price target on CVS Health and gave the stock a buy rating in a report on Monday, October 21st. SunTrust Banks lifted their price target on CVS Health to $85.00 and gave the stock a buy rating in a report on Thursday. ValuEngine raised CVS Health from a strong sell rating to a sell rating in a research report on Wednesday, October 2nd. Morgan Stanley raised their target price on CVS Health from $74.00 to $77.00 and gave the stock an overweight rating in a research report on Thursday, September 26th. Finally, Evercore ISI set a $63.00 target price on CVS Health and gave the stock a buy rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $77.59.

CVS Health stock traded up $0.69 during mid-day trading on Thursday, reaching $72.47. 9,079,719 shares of the company’s stock were exchanged, compared to its average volume of 6,966,567. The business’s fifty day simple moving average is $64.66 and its 200 day simple moving average is $58.54. The firm has a market capitalization of $87.55 billion, a PE ratio of 10.24, a P/E/G ratio of 1.46 and a beta of 0.86. CVS Health has a one year low of $51.72 and a one year high of $82.15. The company has a quick ratio of 0.64, a current ratio of 0.95 and a debt-to-equity ratio of 1.39.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.84 EPS for the quarter, topping the Zacks’ consensus estimate of $1.77 by $0.07. The business had revenue of $64.81 billion for the quarter, compared to analyst estimates of $62.99 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. CVS Health’s quarterly revenue was up 36.5% compared to the same quarter last year. During the same period last year, the company posted $1.73 earnings per share. On average, sell-side analysts forecast that CVS Health will post 6.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, November 4th. Stockholders of record on Thursday, October 24th were given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.76%. The ex-dividend date was Wednesday, October 23rd. CVS Health’s dividend payout ratio (DPR) is presently 28.25%.

In other news, CFO Eva C. Boratto sold 8,130 shares of CVS Health stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $65.00, for a total value of $528,450.00. Following the completion of the transaction, the chief financial officer now directly owns 55,273 shares in the company, valued at $3,592,745. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joshua Matthew Flum sold 17,703 shares of CVS Health stock in a transaction on Monday, September 30th. The shares were sold at an average price of $63.00, for a total value of $1,115,289.00. Following the completion of the transaction, the executive vice president now owns 36,163 shares of the company’s stock, valued at $2,278,269. The disclosure for this sale can be found here. Over the last quarter, insiders sold 49,437 shares of company stock valued at $3,248,811. 0.53% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. MUFG Americas Holdings Corp grew its position in shares of CVS Health by 33.0% in the third quarter. MUFG Americas Holdings Corp now owns 53,966 shares of the pharmacy operator’s stock valued at $3,404,000 after purchasing an additional 13,393 shares in the last quarter. First Allied Advisory Services Inc. grew its position in CVS Health by 12.0% during the third quarter. First Allied Advisory Services Inc. now owns 66,850 shares of the pharmacy operator’s stock worth $4,217,000 after buying an additional 7,160 shares in the last quarter. Signet Investment Advisory Group Inc. grew its position in CVS Health by 4.3% during the third quarter. Signet Investment Advisory Group Inc. now owns 22,692 shares of the pharmacy operator’s stock worth $1,431,000 after buying an additional 935 shares in the last quarter. Cetera Advisor Networks LLC grew its position in CVS Health by 10.8% during the third quarter. Cetera Advisor Networks LLC now owns 46,315 shares of the pharmacy operator’s stock worth $2,914,000 after buying an additional 4,533 shares in the last quarter. Finally, Trillium Asset Management LLC grew its position in CVS Health by 2.3% during the third quarter. Trillium Asset Management LLC now owns 266,172 shares of the pharmacy operator’s stock worth $16,787,000 after buying an additional 6,075 shares in the last quarter. Institutional investors own 76.17% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

See Also: What is the Book Value of a Share?

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.